Small cell (Neuroendocrine) carcinoma of the prostate

Etiology, diagnosis, prognosis, and therapeutic implications-A retrospective study of 30 patients from the rare cancer network

Moshe E. Stein, Zvi Bernstein, Ufuc Abacioglu, Meric Sengoz, Robert C. Miller, Amichai Meirovitz, Abadou Zouhair, Salvador Villá Freixa, Philip H. Poortmans, Robert Ash, Abraham Kuten

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Within the framework of the Rare Cancer Network Study, we examined 30 patients suffering from small cell neuroendocrine prostate cancer, either in an early/localized or an advanced/metastatic stage. Patients were treated with cisplatin-based chemotherapy, with or without pelvic radiotherapy. Two patients with early disease achieved complete remission for a duration of 19 and 22 months. Three patients with advanced disease achieved complete remission for 6, 7, and 54 months, respectively. Twenty-five patients succumbed to massive local and/or distant failure. No patient presented with brain metastases as the initial site of relapse. Small cell neuroendocrine prostate carcinoma is a very aggressive disease with a poor prognosis, even in its localized form. Despite initial response, the common cisplatin-based chemotherapy plus radiotherapy failed to improve outcome markedly. Improvement will come from understanding the biology of the disease and integrating new targeted therapies into the treatment of this rare and aggressive tumor.

Original languageEnglish (US)
Pages (from-to)478-488
Number of pages11
JournalAmerican Journal of the Medical Sciences
Volume336
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Neuroendocrine Carcinoma
Small Cell Carcinoma
Prostate
Retrospective Studies
Neoplasms
Cisplatin
Radiotherapy
Therapeutics
Drug Therapy
Neuroendocrine Cells
Prostatic Neoplasms
Neoplasm Metastasis
Recurrence
Brain

Keywords

  • Prostate
  • Small cell carcinoma
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Small cell (Neuroendocrine) carcinoma of the prostate : Etiology, diagnosis, prognosis, and therapeutic implications-A retrospective study of 30 patients from the rare cancer network. / Stein, Moshe E.; Bernstein, Zvi; Abacioglu, Ufuc; Sengoz, Meric; Miller, Robert C.; Meirovitz, Amichai; Zouhair, Abadou; Freixa, Salvador Villá; Poortmans, Philip H.; Ash, Robert; Kuten, Abraham.

In: American Journal of the Medical Sciences, Vol. 336, No. 6, 12.2008, p. 478-488.

Research output: Contribution to journalArticle

Stein, Moshe E. ; Bernstein, Zvi ; Abacioglu, Ufuc ; Sengoz, Meric ; Miller, Robert C. ; Meirovitz, Amichai ; Zouhair, Abadou ; Freixa, Salvador Villá ; Poortmans, Philip H. ; Ash, Robert ; Kuten, Abraham. / Small cell (Neuroendocrine) carcinoma of the prostate : Etiology, diagnosis, prognosis, and therapeutic implications-A retrospective study of 30 patients from the rare cancer network. In: American Journal of the Medical Sciences. 2008 ; Vol. 336, No. 6. pp. 478-488.
@article{dc576d84e60844fc868d86ad395bc3dd,
title = "Small cell (Neuroendocrine) carcinoma of the prostate: Etiology, diagnosis, prognosis, and therapeutic implications-A retrospective study of 30 patients from the rare cancer network",
abstract = "Within the framework of the Rare Cancer Network Study, we examined 30 patients suffering from small cell neuroendocrine prostate cancer, either in an early/localized or an advanced/metastatic stage. Patients were treated with cisplatin-based chemotherapy, with or without pelvic radiotherapy. Two patients with early disease achieved complete remission for a duration of 19 and 22 months. Three patients with advanced disease achieved complete remission for 6, 7, and 54 months, respectively. Twenty-five patients succumbed to massive local and/or distant failure. No patient presented with brain metastases as the initial site of relapse. Small cell neuroendocrine prostate carcinoma is a very aggressive disease with a poor prognosis, even in its localized form. Despite initial response, the common cisplatin-based chemotherapy plus radiotherapy failed to improve outcome markedly. Improvement will come from understanding the biology of the disease and integrating new targeted therapies into the treatment of this rare and aggressive tumor.",
keywords = "Prostate, Small cell carcinoma, Treatment",
author = "Stein, {Moshe E.} and Zvi Bernstein and Ufuc Abacioglu and Meric Sengoz and Miller, {Robert C.} and Amichai Meirovitz and Abadou Zouhair and Freixa, {Salvador Vill{\'a}} and Poortmans, {Philip H.} and Robert Ash and Abraham Kuten",
year = "2008",
month = "12",
doi = "10.1097/MAJ.0b013e3181731e58",
language = "English (US)",
volume = "336",
pages = "478--488",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Small cell (Neuroendocrine) carcinoma of the prostate

T2 - Etiology, diagnosis, prognosis, and therapeutic implications-A retrospective study of 30 patients from the rare cancer network

AU - Stein, Moshe E.

AU - Bernstein, Zvi

AU - Abacioglu, Ufuc

AU - Sengoz, Meric

AU - Miller, Robert C.

AU - Meirovitz, Amichai

AU - Zouhair, Abadou

AU - Freixa, Salvador Villá

AU - Poortmans, Philip H.

AU - Ash, Robert

AU - Kuten, Abraham

PY - 2008/12

Y1 - 2008/12

N2 - Within the framework of the Rare Cancer Network Study, we examined 30 patients suffering from small cell neuroendocrine prostate cancer, either in an early/localized or an advanced/metastatic stage. Patients were treated with cisplatin-based chemotherapy, with or without pelvic radiotherapy. Two patients with early disease achieved complete remission for a duration of 19 and 22 months. Three patients with advanced disease achieved complete remission for 6, 7, and 54 months, respectively. Twenty-five patients succumbed to massive local and/or distant failure. No patient presented with brain metastases as the initial site of relapse. Small cell neuroendocrine prostate carcinoma is a very aggressive disease with a poor prognosis, even in its localized form. Despite initial response, the common cisplatin-based chemotherapy plus radiotherapy failed to improve outcome markedly. Improvement will come from understanding the biology of the disease and integrating new targeted therapies into the treatment of this rare and aggressive tumor.

AB - Within the framework of the Rare Cancer Network Study, we examined 30 patients suffering from small cell neuroendocrine prostate cancer, either in an early/localized or an advanced/metastatic stage. Patients were treated with cisplatin-based chemotherapy, with or without pelvic radiotherapy. Two patients with early disease achieved complete remission for a duration of 19 and 22 months. Three patients with advanced disease achieved complete remission for 6, 7, and 54 months, respectively. Twenty-five patients succumbed to massive local and/or distant failure. No patient presented with brain metastases as the initial site of relapse. Small cell neuroendocrine prostate carcinoma is a very aggressive disease with a poor prognosis, even in its localized form. Despite initial response, the common cisplatin-based chemotherapy plus radiotherapy failed to improve outcome markedly. Improvement will come from understanding the biology of the disease and integrating new targeted therapies into the treatment of this rare and aggressive tumor.

KW - Prostate

KW - Small cell carcinoma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=59049096202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59049096202&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0b013e3181731e58

DO - 10.1097/MAJ.0b013e3181731e58

M3 - Article

VL - 336

SP - 478

EP - 488

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 6

ER -